Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Vir Biotechnology, Inc.NASDAQ: VIR

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin remains negative

Q1 FY2026 selling, general & admin was $23.34M, compared with $0 a year earlier. Trailing-twelve-month selling, general & admin was $69.19M.

Context

  • Selling, general & admin amounted to 134.3% of revenue in FY2025, up 134.3 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $344.2M (+273.8%) for the fiscal year ending Dec 2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.34M-1.2% QoQ
Last fiscal yearDec 2025
$92.07M— YoY
LTMMar 2026
$69.19M— YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+273.8%—
3-year CAGR—+4.5%—
5-year CAGR+30.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
92.07M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Selling, general & admin amounts to 105.6% of revenue for VIR, versus a peer median of 32.9%.
VIR Competitors
Selling, General & Admin for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$979M USD-7.7%-3.5%38.8%
BNTXBioNTech SELTM Jun 2026€788.8M EUR+45.9%+8.9%29.8%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$337.33M USD+6.9%+29.8%35.9%
NVAXNovavax, Inc.LTM Mar 2026$127.98M USD-57.1%-32.5%21.5%
VALNValneva SELTM Mar 2026€70.46M EUR-23.0%+9.1%45.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$69.19M USD——105.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$38.28M USD-25.4%-1.1%55.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$30.28M USD-34.0%-12.3%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$19.78M USD+10.8%-6.4%27.8%
ABUSArbutus Biopharma CorporationLTM Mar 2026$15.94M USD-39.5%-3.8%8.3%
Peer median (excluding VIR) —-23.0%-3.5%32.9%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.